Plenary sessions

PL.01 - Plenary session 1

PL01.1 ANTIMICROBIAL RESISTANCE IN *NEISSERIA GONORRHOEA* AND POSSIBLE EMERGENCE OF UNTREATABLE GONORRHOEA: HOW, WHEN AND ESSENTIAL ACTIONS?

doi:10.1136/sextrans-2013-051184.0002

M Unemo. *Orebro University Hospital, Orebro, Sweden*

The WHO estimated 106 million gonorrhoea cases in 2008 globally and antimicrobial resistance (AMR) in *Neisseria gonorrhoeae* is a major public health concern that compromises effective treatment and disease control efforts worldwide. The new superbug *Neisseria gonorrhoeae* has retained high-level resistance to antimicrobials previously recommended for first-line treatment and, recently, the first extensively drug-resistant (XDR) gonococcal strains with high-level resistance to the extended-spectrum cephalosporin (ESC) ceftriaxone, the last remaining option for first-line empiric monotherapy of gonorrhoea, were reported. This is of grave concern and it is feared that gonorrhoea may become untreatable under certain circumstances. In this talk, with particular emphasis on ESCs the evolution, origin, emergence and spread of AMR and genetic AMR determinants; their relevance and effects (including interplay and epistasis) on AMR and biological fitness of gonococcal strains; gonococcal population dynamics and international spread of biologically "successful" AMR gonococcal clones; genetic AMR detection methods; current situation regarding verified treatment failures with ESCs, and suggested future treatment options will be discussed. Essential actions to combat the emergence of multidrug resistant and possibly untreatable gonorrhoea will also be highlighted, such as implementing the WHO Global Action Plan and national or regional action/response plans, e.g., the ECDC Response plan for the European Union and the CDC Response Plan for the USA; enhancing surveillance of gonococcal antimicrobial resistance, treatment failures and antimicrobial use/misuse; and improving prevention, early diagnosis and treatment of gonorrhoea to reduce the gonorrhoea burden. All these responses will be valuable in detaining the global spread of AMR, however, in a longer term not sufficient to prevent the emergence and spread of potentially untreatable gonorrhoea. Few promising new antimicrobials are in sight, and it is essential to promptly focus research on timely development of novel effective drugs for treatment of gonorrhoea, and ideally, a vaccine.

PL01.2 HPV: CHANGING SCREENING ALGORITHMS AND SCALING UP VACCINATION

doi:10.1136/sextrans-2013-051184.0003

E L Franco. *McGill University, Montreal, QC, Canada*

Since 2006, when the first human papillomavirus (HPV) vaccine was approved, there has been much progress on the prevention of diseases associated with HPV infection, particularly cervical cancer. A decade earlier, the first clinically validated HPV assay was approved as an adjunct test in cervical cancer screening. As the two cervical cancer prevention fronts, i.e., primary via vaccination and secondary via screening, progressed more or less in parallel they have begun to intersect in recent years, as it has become clear that effective deployment of these strategies requires integration of resources and planning. However, acceptance of these technologies has not been without obstacles. Up until recently, although the evidence for the superior value of HPV testing in cervical cancer screening had become unequivocal, consensus guidelines in the U.S.

tended to indicate uncertainty as to the degree and strength of evidence associated with this test. This state of affairs changed in March 2012 with the simultaneous publication of the guidelines from the US Preventive Services Task Force and from the joint society consortium that involved the American Cancer Society, the American Society for Colposcopy and Cervical Pathology, and the American Society of Clinical Pathology. These guidelines placed greater emphasis on HPV testing in primary screening and discouraged unnecessary screening at younger ages and overly frequent screening. While co-testing is still favoured by the new US guidelines, other high-resource countries began to pilot or even to implement programmatically the strategy of HPV testing as the sole primary screening test, reserving Pap cytology for the triage of women who are HPV positive. The author will review the historical milestones of how HPV-based strategies have moved to centre stage in cervical cancer prevention and discuss the research directions in the area, particularly with respect to how these strategies intersect.

PL.02 - Plenary session 2

PL02.1 THE DYNAMIC EVOLUTION OF SEXUAL BEHAVIOR AS IT IMPACTS STD SPREAD

doi:10.1136/sextrans-2013-051184.0004

S Aral. *Centers for Disease Control and Prevention, Atlanta, GA, United States*

The past three decades have been marked by significant progress in our understanding of the biological foundations of human behaviour, the evolutionary forces that drive human conduct and cognition and environmental factors that turn genes on and off. Concurrently, advances in communication technologies have drastically changed the way people meet and mate; demographic trends have modified patterns of supply and demand of potential mates while economic trends have affected men and women's motivations for sexual partnering.

Consequent changes in sexual values, attitudes and norms; sexual behaviours including sexual practises; and concepts of marriage, commitment, love and sex have been remarkable. Major trends in sexual behavioural determinants of sexually transmitted infection spread include: exponential increases in the size of sexual core groups; increased acceptance of commercial and transactional sex; increases in male, female and underage sex tourism; and increased geographic mobility of sex workers. These trends result in greater connectedness among sexual core groups across national boundaries thereby limiting the effectiveness of national prevention programmes. Moreover, both increased sexual mixing between core groups and the general population and increased reporting about sexual core behaviours through social media facilitate behavioural contagion and enhance the impact of sexual core groups on the behaviours of the general population. It is surprising that STI are not spreading faster globally in light of these changes in their social and behavioural determinants.

PL02.3 HIV TRANSMISSION DYNAMICS; CAN WE TRANSLATE KNOWLEDGE INTO ACTION

doi:10.1136/sextrans-2013-051184.0005

^{1,2}**T C Quinn.** ¹*National Institute of Allergy and Infectious Diseases, Baltimore, MD, United States;* ²*Johns Hopkins University, Baltimore, MD, United States*

Background There are 34 million people living with HIV globally, and 2.5 million people become newly infected last year. Although there have been some successes in prevention, the epidemic continues unabated in many populations, requiring more intensive and integrated behaviour and biomedical prevention programmes if we are to control HIV spread.

Methods A comprehensive review of randomised trials of behavioural and biomedical interventions aimed at decreasing HIV transmission and acquisition was performed and will be presented.

Results In addition to male circumcision, the most successful biomedical intervention has been the use of antiretroviral drugs (ARVs) for prevention of HIV perinatal transmission and sexual transmission among HIV discordant couples, and for the prevention of HIV acquisition via microbicides and oral pre-exposure prophylaxis (PrEP). All of the transmission studies have demonstrated that reductions in viral load with ARVs to undetectable viral blood levels during birth, breast-feeding, or sexual intercourse reduces transmission by > 96%. This has been the greatest success in the HIV prevention field over the past two decades and continual scale-up of access to ARVs can be associated with marked reductions in HIV transmission and incidence. Decreasing acquisition with use of ARVs is totally dependent on high adherence (> 90%) to the medications in an uninfected population. Studies have had mixed results with some populations with high adherence demonstrating high efficacy using PrEP (> 70% efficacy) or microbicide (> 50% efficacy), while others with low adherence as measured by non-detectable blood levels of ARVs demonstrated no efficacy.

Conclusion Multiple studies have confirmed that effective use of ARVs substantially reduces transmission and emphasise the critical importance of integrated behavioural and biomedical strategies. When treatment with ARVs is combined with other interventions involving voluntary counselling and testing, condoms, adherence to medications, and circumcision, the possibility of controlling HIV becomes a feasible and achievable goal.

PL.03 - Plenary session 3: Anton Luger Memorial

PL03.1 STIS - 2013: RESURGENCE OF EARLY SYPHILIS, PERSISTENCE OF HIGH STI MORBIDITY AND MORTALITY, AND EMERGENCE OF ANTIMICROBIAL RESISTANT STIS: IMPLICATIONS AND POTENTIAL RESPONSES

doi:10.1136/sestrans-2013-051184.0006

K Holmes. *University of Washington, Seattle, WA, United States*

Recent directions in clinical-epidemiologic research on STIs include (1) population-level estimates of STI prevalence (e.g., WHO's 2011 publication of global estimates), and formal population-level surveys of STI prevalence and risk determinants; (2) analysis of global mortality and disability attributable to major diseases, including STIs (the Global Burden of Disease Study, published in the December 2012 triple issue of *The Lancet*); (3) conceptualization and implications of the "Treatment and Care Cascade" and the "Prevention Cascade" currently focused on HIV infection; and (4) emerging interest in Program Science, linking programme implementers and scientists in needs assessments, conceptualization, design, advocacy for funding, implementation, evaluation, cost-effectiveness, and continuous strengthening of STI/HIV programmes. The global emergence and rapid spread of anti-microbial resistant pathogens, suggests the clinical mantra of "first do no harm" to the individual patient must be mirrored in a similar public health mantra - "first do no harm" to the population. This means selective use and more systematic evaluation of the impact of anti-microbial use on human and animal pathogens and microbiomes. The reemergence of syphilis and persistence of other STIs in vulnerable populations, and the limited implementation of cost-effective interventions for STI control reflects global neglect of STI programmes, and perhaps increasing failure to effectively integrate STI, HIV/AIDS, and reproductive health programmes globally (for example, the very limited integration of HIV PMTCT with elimina-

tion of congenital syphilis programmes). Nonetheless, progress in sexual health promotion and STI control can be made possible with cost-effective use by clinicians and public health leaders of effective, available tools, such as scale up of HPV and HBV vaccines, and linked delivery of other sociobehavioral and biomedical STI interventions in vulnerable populations. Rigorous evaluation of the impact of such programmes, with assessment of what is not working as well as what is working, is essential.

PL03.2 CONTROL OF SYPHILIS IN THE WORLD'S MOST POPULOUS COUNTRY: OPPORTUNITIES AND CHALLENGES

doi:10.1136/sestrans-2013-051184.0007

X Chen. *National Center for STD Control, Nanjing, China*

As one of the major sexually transmitted infections (STIs), syphilis has made a strong resurgence in China at a rate faster than any other country since 1980s. Epidemic of the infection has focused on the groups most at risk, such as men who have sex with men (MSM), female sex workers (FSWs), particularly those women working in the service venues or on the streets, and migrants. In recent years, the Chinese government has increased its efforts to respond the epidemic. Specifically, the Ministry of Health's recently launched 10-year national syphilis control and prevention plan includes the national milestone of achieving an explicit decline in the reported syphilis incidence and the elimination of congenital syphilis by 2020, indicating specific targets for percentages of target populations educated about syphilis, tested and treated for syphilis. Increasing political commitment, innovative screening technologies, and functional health systems have provide opportunities for China to develop the comprehensive intervention package consisting of "One integration of behavioural prevention, Two systems to be strengthened, and Three active screening accesses to high-risk groups to link One standardised treatment at clinic" to highlight the combination of behavioural and biomedical interventions for achieving the goals of the national plan. However, many significant challenges at programing and implementation levels, such as capacity of health system, affordability to STI care, trust between public health providers and clients, access to hidden populations, social stigma, confidentiality, and micro-environment to support delivery of intervention and care, still remain.

PL03.3 SYPHILIS: FROM PATHOGENESIS TO CONTROL

doi:10.1136/sestrans-2013-051184.0008

S A Lukehart. *University of Washington, Seattle, WA, United States*

Syphilis is one of the most fascinating of all infections. Although its origin is still debated, the history of syphilis includes many famous (and infamous) persons, and the disease is featured in art and literature. Syphilis is caused by a corkscrew-shaped bacterium, *Treponema pallidum*, that was first identified over 100 years ago. It has a minuscule genome, and it lacks many of the common metabolic pathways. It is so fragile that it dies within hours outside of the host, yet it is capable of evading host defences to persist for decades within the host.

Syphilis is known as "the great imitator" because its clinical manifestations, which can range from an ulcer or rash to blindness and insanity, can be mistaken for many other clinical conditions. In contrast, the infection can lie smouldering for many years, without any clinical evidence. After 70 years of use, penicillin continues to be an effective treatment, yet resistance to macrolide antibiotics like azithromycin has erupted in *T. pallidum* in many regions of the world. Physicians recognise that some persons who are treated for syphilis can be reinfected, sometimes multiple times. At the population level, the incidence of syphilis can wax and wane, often shifting from one population group to another.